The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]
Videos
The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center shared his experiences engaging with a diverse community of clinicians at the ATMRD Congress and in clinical practice. [WATCH TIME: 2 minutes]
Scott Newsome, DO, and Ellen Mowry, MD, discuss the ongoing TREAT-MS trial and its goals, the importance of the findings for clinical practice in multiple sclerosis, and the ongoing discussion around induction vs escalation in MS treatment. [WATCH TIME: 24 minutes]
James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, review the role of complement inhibitors and FcRn inhibitors in the management of myasthenia gravis.
Thought leaders review the role of non-pharmacological strategies to manage myasthenia gravis comorbidities.
The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]
The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending July 9, 2022. [WATCH TIME: 4 minutes]
The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]
Kelly Knupp, MD, provides an overview of Lennox-Gastaut Syndrome (LGS).
Joseph E. Sullivan, MD, and Kelly Knupp, MD, share strategies for managing patients who have suboptimal seizure control with medications.
The pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]
Ahmed Obeidat, MD, PhD, comments on other viruses that have been linked to the development of multiple sclerosis and discusses how they can be both protective and detrimental.
Amit Bar-Or, MD, FRCPC, and Bridget A. Bagert, MD, share their opinions on the role the Epstein-Barr virus plays in the development of multiple sclerosis, highlighting recent publications examining this link.
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided insight on a unique way the institution cares for patients who present with an inflammatory or autoimmune entity. [WATCH TIME: 5 minutes]
Drs Jeffrey Dunn and Regina Berkovich provide insight into the biochemistry and reversibility of currently available S1P treatments for patients with multiple sclerosis.
Experts in neurology comment on factors relating to treatment selection in pregnancy for women with multiple sclerosis; highlighting efficacy and reversibility considerations of disease-modifying therapies.
Dr Ericka Wong discusses treatment options available to patients with initial myasthenia gravis, patients with acute exacerbation, and patients with refractory myasthenia gravis.
Ericka Wong, MD, discusses the challenges in the treatment of myasthenia gravis and the burden of myasthenia gravis.
Rachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.
Chaired by Stephen Krieger, MD, the presentations also feature Mount Sinai experts Erin Beck, MD, PhD; James Sumowski, PhD; and Ilana Katz Sand, MD. [WATCH TIME: 1 hour, 34 minutes]
Heidi Crayton, MD, comments on cognitive and brain health considerations in patients with multiple sclerosis and shares her experiences with both patients and their caregivers.
An expert in neurology provides insight into the considerations of oral versus injectable therapies in patients with multiple sclerosis, highlighting their impact on quality of life, brain volume, and cognitive health.
Experts in neurology comment on the level of patient awareness surrounding cognitive decline in multiple sclerosis and highlight how to engage patients in difficult conversations regarding their cognitive health.
Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, share their practices and diagnostic assessments for cognitive decline in their patients with multiple sclerosis.
Dr DeLuca shares his advice and recommendations from National MS Society on providing cognitive care for patients suffering from MS.
Multiple sclerosis expert, Dr DeLuca, shares study design and clinical data on the association between brain volume and long-term cognition in patients with relapsing MS.
A comprehensive review of drugs to avoid when designing treatment plans for patients with myasthenia gravis.
Experts recommend approaches for special cases including ocular myasthenia gravis, pregnant patients and children with myasthenia gravis, and more.
The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital and presenter at ATMRD offered his insight into the benefits of multispecialty meetings. [WATCH TIME: 1 minute]
Advertisement
Advertisement
